• Tags: AMD
Study: MacTel prevalence climbing faster than AMD
Research

Study: MacTel prevalence climbing faster than AMD

Prevalence nearly doubled between 2015 and 2024, with the rate of increase outpacing AMD and diagnoses most common among adults ages 65 to 74.
i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD
Pipeline

i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD

Expanded clinical findings from U.S.-based feasibility trial include a ≥10-ETDRS letter improvement among over 50% of treated patients.
Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3B
Business

Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3B

Pending transaction includes phase 3 funding for OLN324, an investigational bispecific antibody under evaluation for wet AMD and DME.
IMVIONIX debuts with acquisition of BEOVU's North American rights
Business

IMVIONIX debuts with acquisition of BEOVU's North American rights

Biotech company launches to commercial space; secures U.S. and Canadian exclusive rights to the FDA-approved injection for wet AMD and DME.
EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
Pipeline

EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout

LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation
Pipeline

Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation

Company reports a constructive meeting with the FDA over a planned trial evaluating oral tonabersat; currently eyeing a 2027 timeframe for kickoff.
Merck releases phase 2b/3 DME data for tri-specific antibody
Pipeline

Merck releases phase 2b/3 DME data for tri-specific antibody

Topline data demonstrates non-inferiority and higher rates of two AEs and treatment discontinuation due to AEs.
Kodiak's tarcocimab meets wet AMD phase 3 endpoint, targets Q4 BLA
Pipeline

Kodiak's tarcocimab meets wet AMD phase 3 endpoint, targets Q4 BLA

Zenkuda and KSI-501 both met the primary endpoint in DAYBREAK study, accelerating Kodiak’s development plans.
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI
Pipeline

Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI

Company remains on track for a Q4 2026 submission; wet AMD IVT implant has the potential for long-term durability and fewer injections.
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
Pipeline

Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy

EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Pipeline

EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial

Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Research

Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD

Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
NSAID use may lower AMD risk
Research

NSAID use may lower AMD risk

Prescribed patients appear less likely for disease development, with the association observed across multiple AMD subtypes and several commonly used medications
4DMT reports new phase 2b gene therapy data for wet AMD
Pipeline

4DMT reports new phase 2b gene therapy data for wet AMD

New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.
Biocon launches Eylea biosimilar to US market
Products

Biocon launches Eylea biosimilar to US market

With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Adverum reports 5-year extension data on wet AMD gene therapy
Research

Adverum reports 5-year extension data on wet AMD gene therapy

At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.
FDA approves Outlook's LYTENAVA for wet AMD
Products

FDA approves Outlook's LYTENAVA for wet AMD

The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Mediterranean diet linked to slower AMD progression
Research

Mediterranean diet linked to slower AMD progression

Diet aherence associated with slower AMD progression at every disease stage, with specific food components mattering most depending on the stage.
New SYFOVRE data extend GA benefit to patients with concurrent wet AMD
Research

New SYFOVRE data extend GA benefit to patients with concurrent wet AMD

SYFOVRE demonstrates reduced photoreceptor and RPE loss in GA patients and those with concomitant nAMD.
Oculgen enrolls first US patient in global phase 2/3 wet AMD trial
Pipeline

Oculgen enrolls first US patient in global phase 2/3 wet AMD trial

Company aims to utilize 36-week data from the STAT trial to support a BLA following its recent IND approval.